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DNA was puriﬁed from activated peripheral blood mononuclear cells (PBMCs) and PCR was used to detect
XMRV gag and env in 72 patients. Anti-XMRV antibodies were searched in sera of 62 patients by Western
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ly, detection of infectious virus in 113 CFS subjects was made by co-culture of PHA+IL-2 activated PBMC
with human LNCaP carcinoma cells, and by infecting the same susceptible cells with plasma, using a reverse
transcriptase (RT) assay as a readout in both experiments. No detection of XMRV footprints nor infectious
virus was detected with any of the approaches, in any of the tested individuals.of Montreal, 110 Pine Avenue
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Chronic fatigue syndrome (CFS) is an ill-deﬁned illness for which
there is no diagnostic markers (Chaudhuri and Behan, 2004; Gibson,
2007; Wyller, 2007). Various pathogenic agents have been associated
with this syndrome, but its etiology remains unknown (Wyller,
2007). Recently, footprints of a novel murine retrovirus, xenotropic
murine leukeamia virus-related virus (XMRV) have been detected in
a very high percentage of CFS individuals living in United States
(Lombardi et al., 2009). Moreover, infectious XMRV could be isolated
from peripheral blood mononuclear cells (PBMCs) or plasma originat-
ing from some of these patients, using susceptible cells (Lombardi et
al., 2009). Although these data did not constitute a formal proof that
XMRV represents the etiological agent of CFS, the high percentage
(~67–89%) of CFS subjects harboring XMRV footprints (Lombardi et
al., 2009; Mikovits et al., 2010), makes it a strong candidate for such a
role. The suggestion that amurine retrovirusmay be involved in the de-
velopment of CFS offered very promising perspectives for the diagnosis,
prevention and management of this disease. However, these results
have been controversial and a number of experimental evidence now
indicate that XMRV is unlikely to be present in CFS patients. First,
attempts to conﬁrm Lombardi et al.'s data by several groups workingwith samples from different cohorts of CFS patients were all negative
(Erlwein et al., 2010; Groom et al., 2010; Henrich et al., 2010; Hong et
al., 2010; Switzer et al., 2010; van Kuppeveld et al., 2010; Hohn et al.,
2010; Knox et al., 2011; Furuta et al., 2011; Erlwein et al., 2011; Shin
et al., 2011; Satterﬁeld et al., 2011). Second, two groups found no evi-
dence for the presence of XMRV in some of the same CFS patients
reported to be XMRV-positive by Lombardi et al. (Shin et al., 2011;
Knox et al., 2011). Third, PCR XMRV-positivity is likely to have resulted
from mouse DNA contaminants present in some commercial reagents,
as demonstrated by a number of investigators (Smith, 2010; Sato et
al., 2010; Robinson et al., 2010; Oakes et al., 2010; Hue et al., 2010;
Weiss, 2010; Shin et al., 2011). Fourth, XMRV has recently been
shown to be a very unique laboratory-derived variant replicating in
22Rv1 human prostate carcinoma cells and having a structure almost
identical to that reported for XMRV obtained by Lombardi et al. in CFS
patients (Paprotka et al., 2011). The origin of the virus and its lack of
sequence variations in different CFS patients strongly suggest that its
presence in CFS samples studied by Lombardi et al. was due to laboratory
contaminations.
Because of the tremendous interest initially raised by Lombardi et
al.'s discovery, we also attempted to detect XMRV in a distinct cohort
of CFS patients fromQuebec. For this work, we used various techniques.
In particular, special emphasis was put on detection of infectious XMRV
by long-term culture assays. We report here, as we did in a previous
presentation (Cold Spring Harbor Retroviruses Meeting, 2010), our
failure to detect XMRV in these Québec CFS patients. Our results extend
earlier work to a novel cohort and conﬁrm previous reports on the
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progress.Results
We chose four techniques to detect the presence of XMRV in a co-
hort of CFS subjects: detection of viral DNA and viral proteins in
PBMC, detection of anti-XMRV antibodies and detection of infectious
XMRV.
First, total DNA prepared from PBMC was used to amplify env- and
gag-related fragments of XMRV using various primers (Table 1). DNA
from chronically XMRV-infected 22Rv1 prostate carcinoma cells
(Knouf et al., 2009) was used as a positive control, but wasmanipulated
separately from subject samples by distinct personnel and in a different
room. This control DNA gave a PCR product in each experiment up to di-
lution of 1/105 (Fig. 1A). In contrast, none of the DNAs analyzed from
the ﬁrst group of 72 patients generated similar PCR DNA products in
duplicate experiments and with both gag (n=47) and env (n=72)
primers (Fig. 1B and Table 2). Suspicious fragments,most often of differ-
ent lenght, were further transferred by Southern blotting and hybrid-
ized with
32
P-labeled XMRV-speciﬁc probes. Although this procedure
signiﬁcantly enhanced the sensitivity of the assay, none of the subject
sample DNAs tested gave a positive hybridization signal by this
approach. Failure to detect XMRV sequences was not caused by the
poor quality of the DNAs, as all DNA samples gave a positive PCR signal
with primers for the endogeneous CD4 gene (Fig. 1C). In addition, we
also attempted to detect XMRV viruses in plasma of 9 randomly select-
ed CFS subjects, using a RT-PCR assay on centrifuged virions. This exper-
iment also gave negative results for all tested individuals, while our
positive control supernatant containing XMRV was strongly positive
(Fig. 2).
The second experiment was designed to detect anti-XMRV anti-
bodies (Ab) in serum of CFS subjects. Sera were diluted 1/20 and
used to detect XMRV proteins separated by SDS-PAGE and transferred
by Western blotting. Positive and negative control protein extracts
were from chronically XMRV-infected LNCaP cells and from uninfected
LNCaP cells respectively, both run in parallel on the same strip. Goat
anti-gag p30 Rauscher MuLV antibodies could easily detect XMRV Gag
p30 from infected LNCaP cells on these strips (Fig. 3). To control the
quality of the secondary anti-human IgG Ab used, we carried out an
assay for detecting HIV proteins in Western blot with serum from an
HIV-infected patient. HIV proteins could easily be detected by this pro-
cedure ( data not shown ), indicating that the secondary Ab used was
adequate. However, none of the sera from the ﬁrst group of 62 CFS sub-
jects gave a reproducible and convincing signal in this assay (Fig. 3 and
Table 2), suggesting that anti-XMRV antibodies were either absent or at
too low titers to be detectable by this technique which is less sensitive
than ELISA.
A third method was used for detection of XMRV proteins. It involves
immunoﬂuorescence (IF)with anti-Gag p30RauscherMuLVAb onPBMC
stimulated with PHA+IL-2 for 48–72 h. LNCaP and chronically XMRV-
infected LNCaP cells were used respectively as negative and positive con-
trols for this assay. In all 40 randomly selected patients tested, but two,Table 1
XMRV and human endogenous CD4 gene oligonucleotide primers used for PCR (primer
number from our lab or reference).
5844F env (3078) 5′-GCCTCAGTACAACGTGACAGC-3′ Our lab
5942F env (3051) 5′-GGGGACGATGACAGACACTT-3′ Arnold et al., 2010
6270R env (6273R) 5′-AGCCCACTGAGGAATCAAAACAG-3′ Lombardi
et al., 2009
542F gag (GAG-O-F) 5′-CGCGTCTGATTTGTTTTGTT-3′ Urisman et al., 2006
810R gag (3076) 5′-AGACTTGACCTGAGAGATAATAC-3′ Our lab
hCD4F (790) 5′-GTGGAGGAGCCTTGCCATC-3′ Our lab
hCD4R (791) 5′-GACCACCTTACCTCTGGGC-3′ Our labthe detection of positive cells was negative (Table 2). In one patient,
two cells were clearly positive, but they appeared granular and within
a single cluster, suggesting they may be apoptotic. Similarly, in another
patient, 5–10 granular cells (out of 3×104) were positive, but detection
with the secondary Ab alone gave a similar proportion of
positivity, indicating non-speciﬁc reactions and suggesting that binding
of endogenous proteins with secondary anti-goat immunoglobulins.
Finally, attempts to isolate infectious virus from PBMC of the ﬁrst
group of 63 of these CFS subjects were carried out in a room where no
other murine retrovirus was handled. PBMCs were ﬁrst stimulated
with PHA+IL-2 for 48–72 h. In all cultures, this led to a robust prolifer-
ation which could be observed: cells formed clusters, increased in size
and in numbers. These cells were then co-cultured with susceptible
human LNCaP cells and passaged once every week for 44–76 days.
Virus particles were detected in cell supernatants by a reverse tran-
scriptase (RT) (rA.dT) assay. None of the 63 cultures tested gave a
positive read-out, and all showed RT activity in the range of uninfected
LNCaP cells on 2 to 3 independent tests carried out at different time
points.
Because claims have been made that plasma from CFS patients are
very frequently positive for XMRV (Mikovits et al., 2010), we also car-
ried out infection of LNCaP cells with plasma of all 113 CFS patients
(the ﬁrst 63+50 additional ones recruited later). Plasma diluted
1/10 in PBS (containing 8 μg/ml polybrene) was used to infect
LNCaP cells. None of the 113 samples tested gave a positive result
after culture of LNCaP cells for 37–42 days post-infection. To prove
that the LNCaP cells used for these infections were susceptible to
XMRV, these cells were infected with the virus present in the
supernatant from the 22Rv1 prostate carcinoma cells (Knouf et al.,
2009). At dilution 1/103, the 22Rv1-derived XMRV replicated in LNCaP
cells within 8 days and gave high RT activity (~1×105 cpm). At end-
point dilution, 40 days after infection, the same XMRV-positive control
medium was highly positive (~1×106 cpm) at dilution of 0.5×10−6,
but negative at dilution of 10−6 or higher. Moreover, 22Rv1-derived
XMRV diluted 1/500 in PBS or in 1/10 plasma (as the patients samples)
gave similar read-outs, indicating that the plasma did not signiﬁcantly
reduce sensitivity of the assay. Because our experiments yielded all neg-
ative results, we were interested in comparing our methodology on
samples from patients reported to be positive by Lombardi et al.
(2009). Several attempts to obtain such samples were unsuccessful.
However, through personal contacts, we were able to have access to
the blood sample from one CFS patient residing in Canada and whose
blood has been tested positive by the Viral Immune Pathology Disgnos-
tics (Redlabs, USA Inc., Reno, Nevada), using the "XMRV viral culture
DNA detection" assay. Plasma and PHA-activated PBMC from this pa-
tient used respectively for infection of and co-culture with LNCaP cells
for 40 days, also gave negative results.
A summary of our results is shown in Table 2.
Discussion
Our attempts to detect XMRV DNA, XMRV RNA, anti-XMRV Ab and
XMRV infectious virus in the circulation of subjects with CFS were to-
tally unsuccessful. These data conﬁrm recent studies reporting failure
to detect XMRV in other CFS patients from various regions of the
world (Erlwein et al., 2010; Groom et al., 2010; Henrich et al., 2010;
Hong et al., 2010; Switzer et al., 2010; van Kuppeveld et al., 2010;
Hohn et al., 2010; Satterﬁeld et al., 2011; Furuta et al., 2011; Knox
et al., 2011; Erlwein et al., 2011; Shin et al., 2011) and extend them
by using two distinct very sensitive infectivity assays, on the larger
number of CFS patients reported to-date. Indeed, among the groups
failing to detect XMRV, all used a PCR and/or an antibody detection
approach, but only a few run an infectivity assay involving culture
of plasma or co-culture of PBMC with susceptible cells (Hohn et al.,
2010; Knox et al., 2011; Shin et al., 2011). In a control experiment
with the 22Rv1-derived XMRV, we found that analyzing infected
Fig. 1. Detection of XMRV DNA in PBMC DNA of CFS patients by PCR. (A) 22Rv1 genomic DNAwas diluted in constant same amount of H9 genomic DNA. 7.5 pg of 22Rv1 DNA (10−4)
was sufﬁcient to detect a positive signal equivalent to 20 copies of XMRV (Knouf et al., 2009). A signal was still visible at around 2 copies (10−5) similar to other reports. No de-
tection below one copy of XMRV was observed at 75 fg (10−6). (B) Same reactions as in A on representative PBMC DNAs from patients. (C) The integrity of the DNA samples was
validated by a PCR of human CD4 using the same PCR conditions as those of XMRV ampliﬁcation. Number 1 to 10 are patient DNA samples shown. M is the MWmarker, W is water
and L is the LNCaP DNA positive control.
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high level of sensitivity, our results contrast signiﬁcantly with Lom-
bardi et al.'s study who reported a high success rate at detecting
XMRV in American CFS subjects, at very high levels for some subjects
(Lombardi et al., 2009). The reasons for this discrepancy are not clear.Table 2
Overview of different assays performed to detect XMRV in blood from CFS subjects.
Assays
PCR of PBMC
DNA
RT-PCR of
plasma RNA
RT on su
of LNCaP
co-cultu
env gag
No. patients analyzed 72 47 9 63
No. sample positive for XMRV 0 0 0 0
RT, reverse transcriptase; IF, immunoﬂuorescence; WB, Western blotThese very contrasting results are unlikely to be related to the sen-
sitivity of our techniques, as positive controls used always led to easily
detectable signals. Moreover, the infection and co-culture assays of
LNCaP cells respectively with plasma and activated PBMC used here
was reported by Mikovits et al. (2010), to be the most sensitive forpernatant
cells
red with PBMC
RT on supernatant
of plasma-infected
LNCaP cells
IF of PBMC Serum antigen
reactivity in WB
113 40 62
0 0 0
Fig. 2. Detection of XMRV virions in plasma of CFS patients by RT-PCR. RNAs extracted
from serum of nine (1–9) patients and from the supernatant of 22Rv1 cells (positive con-
trol) were used to run RT-PCR assays with the env primers 5942R/6270F. XMRV env PCR
products separated on agarose gels were detected by ethidiumbromide staining (A) or by
hybridization with
32
P-labeled XMRV env fragment after Southern blotting (B). Note the
presence of XMRV env product in the 22Rv1 cDNA control, equivalent to 1.5 ng
(4.3×108 copy number ssRNA), but its absence in all plasma samples. W, water; L,
LNCaP cell DNA; M, molecular weight marker.
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CFS subjects, culturing cells for 40 days post-infection, was in fact sig-
niﬁcantly more sensitive (possibly in the order of 100–500 folds) than
the assay carried out by Lombardi et al., after only two passages (see
Fig. S5B of Lombardi et al.(2009)). Yet, in this latter ﬁgure, it appears
that, for at least 3 out of the 5 samples analyzed, the vast majority of
the LNCaP cells were infected, as detected by FACS. To reach this
level of infection in LNCaP cells within two passages, we estimated
that the titer of the virus would have to be as high as 10−2–10−3 of
that of the 22Rv1-derived XMRV whose titer is already very high at
0.5×106/ml, as we estimated by end-point dilution. If our CFS patients
would have similar levels of plasma viremia, these would have been
very easy to detect by all the techniques we used. Moreover, in a
later paper about the same patients, Mikovits et al. (2010) reported
a very high detection rate ( ~94%, 48 out of 51 tested samples) by
infecting LNCaP cells with plasma. Considering that our long-termFig. 3. Detection of XMRV Gag proteins in serum of CFS patients byWestern blot analysis. The m
secondary Alexa488-conjugated anti-goat or anti-human Ig antibodies, respectively. (A) Extra
XMRV. (B) Extracts from 22Rv1 (XMRV-positive) cells. (C) Extracts from partially puriﬁed Moculture assay is as sensitive and very likely more sensitive than what
was used by this group, methodology differences are unlikely to ex-
plain this huge difference, especially that a relatively high number of
CFS patients (n=113) were tested.
The discrepancy of our data with those of Lombardi et al. is also
unlikely to come from the choice of the “wrong“ subjects to be
screened, since most of them were investigated in specialized clinics
familiar with the syndrome and were given the diagnosis of CFS.
These include many patients with acute onset and/or very debilitat-
ing disease. Obviously, our cohort is different from the cohort studied
by Lombardi et al. and it is possible that XMRV may be a lot more
prevalent and at higher titers in some cohorts of CFS. Most of our sub-
jects were of French ancestors, while the origin of American subjects
is likely to be more heteregeneous. However, if different cohorts of
CFS subjects show such a highly diverse proportion of XMRV positivity
and levels of active replication, this would strongly argue against the
involvement of XMRV in the development and/or maintenance of the
disease. We cannot rule out either that XMRV may be heterogeneous
enough to be undetectable in the Quebec cohort. It would have to har-
bor sequences divergent enough to prevent PCR primers to attach and
to code for a p30 Gag sufﬁciently different to the point of becoming
unrecognizable by the polyclonal anti-Rauscher p30 Ab used and
which is able to recognize many distinct MuLV strains. Finally, human
LNCaP cells would have to be relatively resistant to such divergent
XMRV. This caveat is also unlikely in view of the highly related sequence
homology of XMRV identiﬁed in CFS patients studied by Lombardi et al.
(2009). However, Lo et al. (2010) recently reported the presence of
MuLV-related polytropic viruses in patients with CFS. If present in our
patients, these MuLVs should have been identiﬁed as efﬁciently as
XMRV itself, with all the techniques we used.
Therefore, although each of the scenarios invoked earlier to
explain discrepancy between our results and those of Lombardi et
al. is possible, they are not very plausible, especially when taken to-
gether. Several reports have raised concerns indeed on possible con-
taminations which could explain some positive PCR results (Smith,
2010; Sato et al., 2010; Robinson et al., 2010; Oakes et al., 2010;
Hue et al., 2010; Weiss, 2010). Moreover, the presence of infectious
XMRV detected by Lombardi et al.(2009) is also likely to be explained
by laboratory contamination, in view of the recent ﬁnding that XMRV
arose as a rare mouse recombinant during serial passages of prostate
cancer cells in nude mice (Paprotka et al., 2011).embranes were reacted with anti-p30 Rauscher MuLV antibodies or patients' serum and
cts from non-infected (NI) LNCaP cells and LNCaP cells infected (I) with 22Rv1-derived
loney virions.
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In conclusion, XMRV was undetectable in the Quebec CFS subjects
screened here with various techniques, indicating that the virus is
either absent or at extremely low levels in these subjects. If XMRV is
involved in the development of this disease, which is highly unlikely
in our view, more sensitive approaches will be needed to detect it, pos-
sibly investigating different cell populations, body ﬂuids or tissues.
Materials and methods
CFS subjects
The 113 CFS patients (a ﬁrst group of 63 and second group of 50
recruited later) were recruited through physicians known to have
experience with and interest in the syndrome as well as through the
Quebec Association of Encephalitis andMyalgia (AQEM), an association
regrouping and supporting patients diagnosed with the syndrome.
They all have been extensively investigated over the years and referred
to specialists interested by the syndrome to rule out major other
abnormalities. Theywere all given the diagnosis of CFS, and themedium
follow-up was 10.3 years. All subjects met the Fukada criteria (Fukuda
et al., 1994). The group of patients consists of 70% females. The protocol
to collect blood and to detect XMRV footprints was approved by the
Human Ethics Committee from the IRCM (Institut de recherches clini-
ques de Montreal). Each patient provided a written consent for the
study.
Preparation and stimulation of PBMC
Blood was collected in commercial EDTA tubes and processed for
PBMC separation within 2 h after collection for all samples, except
11 samples processed after 6 h and 1 sample after 24 h. PBMCs were
separated at room temperature by centrifugation at 1500 rpm for
25 min. on Ficoll gradients (10 ml Ficoll/10 ml blood). PBMCs were
collected, washed once with PBS and frozen in liquid nitrogen in
10% DMS0+90% fetal bovine serum. Over 90% of PBMCs were viable
by trypan blue exclusion when thawed after this freezing procedure.
For stimulation, PBMCs were thawed, washed once in medium to re-
move DMSO and stimulated with PHA-L (Sigma, # L-2769) (2 μg/ml)
for 48 or 72 h. After this incubation period, cells were washed twice
and IL-2 (20 U/ml) was added for the following 24 h of incubation.
All these procedures were carried out in a P3 containment facility
where no mouse cells or viruses were handled.
Detection of XMRV DNA by PCR
DNA was extracted from puriﬁed PBMC with the Qiagen QiAamp
DNA mini-kit (#51304) (Qiagen, Canada, Toronto) and 75 ng of total
DNA was used for PCR reactions in 20 μl, containing Tris 10 mM, KCl
50 mM, MgCl2 1.5 mM, rTaq DNA polymerase (# 27-0798-05) (GE
Healthcare Bioscience Inc., Montreal) 1 U and either env- or gag-speciﬁc
primers (0.3 μM) (Table 1). PCRwas run at 94 °C for 30 s, 59 °C for 30 s,
72 °C for 1 min for 40 cycles. All PCR reactions were performed along
with negative control samples in which water or control DNA replaced
sample DNA. Control positive or negative DNA was extracted respec-
tively from the 22Rv1 and LNCaP cells, both obtained from ATCC. The
22Rv1 prostate carcinoma cell line was shown to produce an XMRV
strain very closely related to that described in CFS patients (Knouf
et al., 2009). These cells have previously been estimated to contain
10–15 copies of integrated XMRV genome (Cornelissen et al., 2010;
Aloia et al., 2010). With 7.5 pg of 22Rv1 cell DNA, equivalent to ~15–
20 copies, as estimated before (Aloia et al., 2010), we could routinely
detect a strong positive signal (Fig. 1A). A fainter signal, equivalent to
1.5–2 copies, was still detectable (Fig. 1A). Subject DNA samples andpositive control DNAs were extracted and handled by different people
in different rooms.Co-culture of PBMC and LNCaP cells
Co-culture were all performed with PBMC which had been fro-
zen, except for 7 samples which were not frozen before. After two
or three days of stimulation with PHA and one day of growth with
IL-2, the stimulated PBMCs were centrifuged and approximately
2×106 cells in 2 ml of medium (RPMI+10% fetal bovine serum+
penicillin/streptomycin) containing polybrene (8 μg/ml) were
added on top of LNCaP cells (1–2.5×105 cells) plated the day before
in 25 cm2 ﬂask. The PBMCs were removed after 3–5 h and LNCaP
cells were fed with 5 ml of medium. These cells were propagated
by trypsinization when they reached near conﬂuence once a week
for 44 to 76 days.Infection of LNCaP cells with plasma
Among the 113 plasma samples analyzed, 63 were from heparin-
ized blood and 50 from EDTA-treated blood. LNCaP cells were seeded
at 1–2×105 cells in 35 mm Petri dishes and infected 24 h later with
0.1 ml plasma diluted 1/10 in RPMI+10% FBSI in the presence of
polybrene (8 μg/ml). After 1 h, 2 ml of medium were added. The
cells were passaged once a week for 37–42 days, and a rA.dT assay
carried out on cell supernatant.Detection of anti-XMRV antibodies (Ab)
LNCaP cells were ﬁrst infected with supernatant from 22Rv1 cells in
the presence of polybrene (8 μg/ml), as previously described (Jolicoeur
and Baltimore, 1976). The presence of XMRV was easily detectable in
these infected cells by rA.dT (N1×106 cpm). LNCaP and chronically
XMRV-infected LNCaP cells were lysed in RIPA buffer and subjected
to SDS-PAGE electrophoresis, as previously described (Vincent et al.,
2006). Strips containing extracts (100 μg) of each cell line were reacted
overnight with serum of each patient at dilution 1/20 and subsequently
with secondary IRDye 800-conjugated anti-human Ig Ab (Rockland), as
previously described (Vincent et al., 2006). For positive controls, goat
anti-Rauscher p30 and p15 Ab were used with Alexa-680-conjugated
anti-goat Ab (Molecular Probes). This control detected easily recogniz-
able p30 and p15 proteins (see discussion), as expected. To control the
quality of the secondary anti-human Ig Ab, we used 293 T cells trans-
fected with HIV-1 DNA, prepared cell extracts and reacted these in
Western blotting with serum from an HIV-1 infected individual and
then with secondary IRDye 800-conjugated anti-human IgG Ab. This
reaction gave a strong positive signal ( data not shown ). All manipula-
tions of 22Rv1-derived XMRV virus and cells infected with it were car-
ried out in a room and a laminar ﬂow hood distinct from those used for
the human subject samples and by different personnel.Immunoﬂuorescence (IF) assay
At the last day after PHA+IL-2 stimulation of PBMC, cells were
collected, ﬁxed with 1% paraformaldehyde and cytospotted at
~50,000 cells per spot. Labeling was done with goat anti-Rauscher
p30 Ab for 2 h and then with secondary Alexa-488 conjugated anti-
goat IgG Ab. Cells were observed with a ﬂuorescent microscope and
compared with cells labeled only with the secondary Ab. LNCaP
cells were used as negative controls and chronically XMRV-infected
LNCaP cells were used as positive controls and these latter gave a
strong reaction.
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Supernatants (1–2 ml) for LNCaP cells co-cultured with PBMC were
collected, centrifuged at ~10,000 rpm for 30 min and resuspended in
100 μl 0.01 M Tris–HCl (pH 8.0) and the reaction carried out in a buffer
containing: Tris 0.05 M pH 8.0, DTT 20 mM, MnCl2 0.6 mM, NaCl
60 mM, oligo-dT1 μg/ml, PolyA 10 μg/ml,
32
P-TTP 10 μCi/ml, TTP
10 μM, NP40 0.05%, essentially as described previously (Jolicoeur and
Baltimore, 1976). The reactions were incubated at 37 °C, and stopped
with 0.1 M Na pyrophosphate and 25% TCA. Nucleic acids were collect-
ed on a glass ﬁlter, washed with 5% TCA and counted in liquid scintilla-
tion counter. Negative controls were supernatants from LNCaP cells.
Positive controls were supernatants from NIH/3 T3 cells chronically
infected with Moloney MuLV, from LNCaP cells chronically infected
with 22Rv1 virus and from 22Rv1 cells. All these positive controls
yielded high reverse transcriptase acitivity (1–2×106 cpm/sample),
while the negative controls yield low counts (100–500 cpm/sample
for plasma infection and 200–2000 cpm/sample for co-culture experi-
ments). Cultures with bordeline results above the background (2000–
3800 cpm/sample) were all retested after additionnal passages and
were uniformely negative.
Detection of viral particles in plasma
Plasmas from heparinized Ficoll-treated 2.5–3 ml blood samples
were centrifuged at 24,000 rpm for 30 min and RNA extracted with
Trizol. From 300 to 600 ng of this nucleic acid preparation, cDNA
was prepared using the M-MLV reverse transcriptase Invitrogen kit
(# 28025–013) (Invitrogen Canada), according to the manufacturer‘s
instructions. A XMRV env PCRwas performed using a tenth of this cDNA
with primers 5942F and 6270F, as described earlier. Positive control
cDNA was prepared by different personnel and in a different room
from 3 ng of nucleic acids extracted from centrifuged viruses present
in the supernatant of LNCaP cells chronically infected with 22Rv1-
derived XMRV. Assuming the absence of DNA or non-viral contamina-
tion, this amount of RNA would correspond to 6×1011 molecules of
XMRV. This positive control was strongly positive (see discussion). In
addition, the XMRV env product was transferred on nylon membrane
by Southern blotting and hybridized with
32
P-labeled 427 bp env
fragment made by PCR with 5844F and 6270F primers, essentially as
described (Girard et al., 1996).
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